Industry Overview - The coal industry is experiencing a comprehensive price increase in the domestic market, driven by heightened demand from downstream sectors such as chemicals due to rising oil prices influenced by geopolitical tensions in the Middle East [6][3]. - As of March 27, the spot reference price for thermal coal in the Bohai Rim was 762 RMB/ton, reflecting a weekly increase of 3.39%, while the Qinhuangdao port price was 761 RMB/ton, up 3.54% [6]. - The metallurgical coal market is also seeing price increases, with main coking coal prices at 1750 RMB/ton, up 8.02%, and 1/3 coking coal at 1380 RMB/ton, up 2.99% [6]. Company Analysis: Aimeike (300896.SZ) - Aimeike reported a revenue of 2.453 billion RMB for 2025, a decrease of 18.94%, and a net profit of 1.291 billion RMB, down 34.05% [9]. - The company’s product lines, particularly solution and gel products, saw significant revenue declines of 27.48% and 26.82% respectively, while new freeze-dried powder products generated 208 million RMB [9]. - Aimeike's gross margin was 92.7%, down 1.94 percentage points, and the net profit margin was 53.07%, down 11.59 percentage points, indicating increased operational costs [9]. Investment Recommendations - The projected earnings per share (EPS) for Aimeike from 2026 to 2028 are estimated at 5, 5.41, and 6.06 RMB, respectively, with a current closing price of 118.74 RMB [8]. - The company is focusing on enhancing its product portfolio through independent research and acquisitions, including a recent acquisition of 85% of South Korea's REGEN for 1.9 million USD, which will strengthen its position in the global aesthetic medicine market [7][9]. - Aimeike's strategic initiatives in R&D and mergers are expected to bolster its capabilities in the aesthetic medicine industry, making it a noteworthy investment opportunity despite current performance pressures [7][9].

[Table_scodeMsg1] 公司研究丨点评报告丨爱美客（300896.SZ） [Table_Title] 爱美客 2025 年年报点评：内生持续承压，期待 26 年新管线落地 报告要点 [Table_Summary] 2025 年全年公司实现营业收入 24.53 亿元，同比下降 18.94%；归母净利润 12.91 亿元，同比 下降 34.05%。2025Q4，公司实现营业收入 5.88 亿元，同比下滑 9.6%，实现归母净利润 1.98 亿元，同比下滑 46.85%。 分析师及联系人 [Table_Author] 李锦 罗祎 SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 丨证券研究报告丨 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_scodeMsg2] 爱美客（300896.SZ） cjzqdt11111 [Table_Title 爱美客 20252]年年报点评：内生持续承压，期待 26 年新管线落地 [Table_Summary2] 事件描述 2025 年全年公司实现营业收入 24 ...

医疗器械 爱美客（300896.SZ） 买入-A(维持) 短期业绩承压，看好公司自主研发+并购布局医美全产业链能力 2026 年 3 月 31 日 公司研究/公司快报 公司近一年市场表现 事件描述 公司发布 2025 年财务报告，期内实现营收 24.53 亿元/-18.94%，归母净 利润 12.91 亿元/-34.05%，扣非归母净利润 10.99 亿元/-41.3%，EPS4.28 元。 其中 2025Q4 实现营收 5.88 亿元/-9.61%，归母净利润 1.98 亿元/-46.85%，扣 非归母净利润 1.22 亿元/-64.14%。公司拟向全体股东每 10 股派发现金红利 8 元（含税）。 事件点评 市场数据：2026 年 3 月 30 日 收盘价（元/股）： 118.74 年内最高/最低（元/股）： 202.88/116. 99 流通 A 股/总股本（亿股）： 2.04/3.03 流通 A 股市值（亿元）： 242.77 总市值（亿元）： 359.30 期内受宏观环境、行业竞争等因素影响，公司溶液类、凝胶类产品营收 呈现不同程度下降。公司溶液类与凝胶类注射产品营收分别为 12.65 亿元、 8. ...

Investment Rating - The report maintains a "Buy-A" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][7]. Core Insights - The company is facing short-term performance pressure but is expected to benefit from its capabilities in independent research and acquisitions across the entire medical beauty industry chain [1][3]. - The company reported a revenue of 2.453 billion yuan for 2025, a decrease of 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [3][9]. - The company is expanding its product matrix with new products in clinical trials and has made strategic acquisitions to enhance its global presence in the medical beauty market [5][9]. Financial Performance - The company’s revenue for Q4 2025 was 588 million yuan, reflecting a decline of 9.61% year-on-year, while the net profit for the same period was 198 million yuan, down 46.85% [3][4]. - The gross margin for the period was 92.7%, a decrease of 1.94 percentage points, and the net profit margin was 53.07%, down 11.59 percentage points [4][9]. - The company plans to distribute a cash dividend of 8 yuan per 10 shares to all shareholders [3]. Future Projections - The expected earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 5.00 yuan, 5.41 yuan, and 6.06 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23.7, 22.0, and 19.6 [7][9]. - Revenue is projected to recover to 2.702 billion yuan in 2026, with a year-on-year growth of 10.2% [9][11].

证券代码：300896 证券简称：爱美客 公告编号：2026-020 号 爱美客技术发展股份有限公司 关于公司控股子公司取得医疗器械注册证书的公告 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公司的 核心竞争力。 上述产品上市后实际销售情况取决于未来市场的推广效果，目前尚无法预测 上述产品对公司未来营业收入的影响，敬请投资者注意投资风险。 1 三、备查文件 1、国家药品监督管理局颁发的关于射频皮肤治疗仪的医疗器械注册证。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱美客技术发展股份有限公司（以下简称"公司"）控股子公司上海维脉医 疗科技有限公司于 2026 年 3 月 30 日收到国家药品监督管理局颁发的《医疗器械 注册证》，具体情况如下： 一、医疗器械注册证的具体情况 | 产品名称 | 注册证编号 | 注册证有效期 | 型号、规格 | 预期用途 | | --- | --- | --- | --- | --- | | | 国械注准 | 自批准之日起有 | | 本产品在医疗机构中，由有资质 的医务人员经培训合格后使用， | | ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a significant performance disclosure period for listed companies, focusing on high-growth sectors such as gold and jewelry, cosmetics, and medical aesthetics, with a notable divergence in performance among consumer brands [4][25] - High-end domestic brands like Laopuhuangjin and Maogeping are showing strong growth, while brands that adapt to channel changes and possess differentiated product capabilities, such as Chaohongji and Shangmei, are also performing well [4][25] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 1.10% and 1.52% respectively during the week of March 23-27, 2026, ranking 19th and 24th among 31 primary industries [6][14] - The jewelry sector saw the highest weekly increase of 1.05%, while the hotel and restaurant sector led year-to-date performance with a 0.77% increase [18][20] Industry Dynamics - The report emphasizes the ongoing annual report disclosures from listed companies, with a focus on high-growth companies [25] - The gold and jewelry sector continues to show a trend towards high-end and fashionable products, with Laopuhuangjin and Chaohongji demonstrating exceptional performance [28][39] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product capabilities, recommending Laopuhuangjin, Chaohongji, and Zhou Dafu [7][42] - Offline retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Jihong Co [7][39] - Cosmetics brands that meet emotional value and safety innovation, recommending Maogeping, Shangmei, and Beitaini [7][40] - Medical aesthetics firms with differentiated products and expanding chains, recommending Aimeike and Meilitiantian Medical Health [7][41] Company-Specific Insights - Laopuhuangjin reported a revenue of 27.303 billion yuan (+221.0%) and a net profit of 4.868 billion yuan (+230.5%) for FY2025, with expectations for continued growth in Q1 2026 [28][41] - Chaohongji achieved a revenue of 9.318 billion yuan (+43.0%) and a net profit of 497 million yuan (+156.7%) for FY2025, with rapid growth in its franchise business [45][46] - Maogeping's revenue reached 5.050 billion yuan (+30.0%) with a net profit of 1.205 billion yuan (+36.8%) for FY2025, showcasing strong performance in high-end channels [32][41] - Shangmei reported a revenue of 9.178 billion yuan (+35.1%) and a net profit of 1.103 billion yuan (+41.1%) for FY2025, with a focus on multi-category growth [32][41]

Investment Rating - The report initiates coverage with an "Overweight" rating for the medical aesthetics industry [6]. Core Insights - The medical aesthetics industry is experiencing steady expansion, with significant potential for increased penetration. The market size in China is projected to grow from 164.7 billion yuan in 2020 to 316.7 billion yuan by 2024, indicating a stable growth trend [6][20]. - The shift in consumer demand is towards continuous aesthetic management rather than one-time procedures, reflecting a maturation in consumer attitudes and acceptance [6]. - The dual drivers of optical technology and injectable materials are propelling market growth, with the laser aesthetics market expected to grow from 3.76 billion yuan in 2024 to 6.26 billion yuan by 2028 [6][44]. - Regulatory improvements are fostering sustainable development in the industry, with multiple policies aimed at standardizing practices and enhancing consumer protection [6][41]. Summary by Sections 1. Medical Aesthetics Industry Overview - The industry is transitioning from a focus on surgical improvements to a more frequent and long-term aesthetic management approach [15]. - The market is expected to grow significantly, with the medical aesthetics market size projected to reach approximately 680 billion yuan by 2030 [20]. - The penetration rate of medical aesthetics in China remains low compared to countries like South Korea and the USA, indicating substantial room for growth [21][23]. 2. Optical Medical Aesthetics Technology - Optical technologies are becoming a core driver of the light medical aesthetics market, with various techniques like laser and radiofrequency gaining traction [43]. - The domestic laser aesthetics market is expected to grow steadily, with a projected market size increase from 3.76 billion yuan in 2024 to 6.26 billion yuan by 2028 [44]. 3. Medical Aesthetics Industry Chain and Key Companies - The report highlights key companies in the medical aesthetics industry, such as Jinbo Biological, Aimeike, and Huadong Pharmaceutical, which have advantages in R&D and product layout [6]. 4. Investment Strategy - The report recommends focusing on companies within the medical aesthetics supply chain that demonstrate strong R&D capabilities and product positioning [6].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 166.67 CNY, while the current price is 122.38 CNY [5][11]. Core Insights - The company's performance is under pressure due to intensified industry competition affecting its main products, alongside rigid costs leading to profit constraints. In 2025, AestheFill contributed 200 million CNY in revenue, and attention is on the subsequent performance and sales progress of botulinum products [2][11]. - Revenue, net profit attributable to the parent company, and net profit excluding non-recurring gains and losses for 2025 are projected to be 2.453 billion CNY, 1.291 billion CNY, and 1.099 billion CNY, respectively, reflecting year-on-year declines of 18.94%, 34.05%, and 41.30% [11]. - The company is expected to face a decline in revenue and profit margins in the short term, but there is potential for recovery driven by new product launches and international expansion strategies [11]. Financial Summary - Total revenue for 2024 is 3.026 billion CNY, projected to drop to 2.453 billion CNY in 2025, with a subsequent recovery to 2.753 billion CNY in 2026 [4][12]. - Net profit attributable to the parent company is expected to decrease from 1.958 billion CNY in 2024 to 1.291 billion CNY in 2025, with a gradual increase to 1.441 billion CNY in 2026 [4][12]. - The company's gross margin for 2025 is projected at 92.70%, down 1.94 percentage points year-on-year, influenced by product mix changes and increased competition [11]. Product Performance - Revenue from solution and gel products is expected to decline by 27% each in 2025, while the newly acquired AestheFill is anticipated to contribute 208 million CNY in revenue [11]. - The company has received approval for its botulinum product, which is expected to enhance its product matrix and potentially mark a turning point for growth [11]. Market Position and Strategy - The company is positioned as a leading player in the upstream market for aesthetic injection products, focusing on channel development and new methodologies for product launches [11]. - The company is actively pursuing internationalization through acquisitions, such as the integration of REGEN, to expand its global footprint and product offerings [11].

Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company is experiencing a transitional period in its product matrix, leading to a decline in performance. Revenue for 2025 is projected at 2.45 billion, down 19% year-on-year, with net profit expected to be 1.29 billion, a decrease of 34% [1][4] - The company is focusing on new product launches and international expansion as key growth drivers, particularly with the upcoming release of new products such as botulinum toxin and minoxidil, alongside the integration of acquired products from the Korean company Regen [4][5] Financial Performance - For 2025, the gross margin, net margin, and adjusted net margin are projected to be 92.7%, 53.1%, and 44.8%, respectively, reflecting declines of 1.9 percentage points, 11.6 percentage points, and 17.1 percentage points year-on-year [2] - The sales expenses have significantly increased due to personnel expansion and higher marketing costs, impacting overall profitability [2] - Revenue breakdown shows that solution and gel products are still in an adjustment phase, with both categories experiencing declines in revenue and sales volume [3] Future Projections - Revenue is expected to recover to 2.91 billion in 2026, with a growth rate of 18.6%, and further increase to 3.54 billion by 2028, with growth rates of 10.5% and 10.3% in subsequent years [4][5] - Net profit is projected to reach 1.47 billion in 2026, with a year-on-year growth of 13.4%, and continue to grow to 1.83 billion by 2028 [5] Market Position - The company is actively expanding its global sales network and has received regulatory approvals for its products in multiple countries, indicating a strong commitment to international market penetration [4]

Investment Rating - The investment rating for the company is "Buy" [3][12]. Core Insights - The company is experiencing a phase of performance pressure, with a focus on both internal growth and external acquisitions to build long-term growth momentum [1][9]. - In 2025, the company reported a revenue of 2.453 billion yuan, a year-on-year decrease of 18.94%, and a net profit attributable to shareholders of 1.291 billion yuan, down 34.05% year-on-year [8][10]. - The company is expanding its product matrix and therapeutic areas, with new product launches and acquisitions aimed at enhancing its competitive edge and international presence [9]. Financial Performance Summary - Revenue projections for the company are as follows: 2024A: 3.026 billion yuan, 2025A: 2.453 billion yuan, 2026E: 2.793 billion yuan, 2027E: 3.084 billion yuan, 2028E: 3.389 billion yuan [2][10]. - The net profit attributable to shareholders is projected to be: 2024A: 1.958 billion yuan, 2025A: 1.291 billion yuan, 2026E: 1.453 billion yuan, 2027E: 1.618 billion yuan, 2028E: 1.802 billion yuan [2][10]. - The earnings per share (EPS) are expected to be: 2024A: 6.47 yuan, 2025A: 4.27 yuan, 2026E: 4.80 yuan, 2027E: 5.34 yuan, 2028E: 5.96 yuan [2][10]. - The price-to-earnings (P/E) ratio is projected to be: 2024A: 18.94, 2025A: 28.72, 2026E: 25.52, 2027E: 22.96, 2028E: 20.58 [2][10]. Operational Analysis - The revenue breakdown for 2025 shows that solution injection products generated 1.265 billion yuan (down 27.48%), gel injection products 890 million yuan (down 26.82%), and freeze-dried powder products 208 million yuan [8]. - The gross margin for the company in 2025 was 92.7%, a decrease of 1.94 percentage points year-on-year [8]. - The company is increasing its investment in sales and R&D, with expense ratios for sales, management, and R&D rising to 15.77%, 7.44%, and 14.67% respectively [8]. Future Outlook - The company is focusing on both internal product development and external acquisitions to drive growth, with new product launches and the acquisition of REGEN to enhance its international market presence [9]. - The company is expected to continue expanding its product offerings and therapeutic areas, which will provide new growth drivers in the medium to long term [9].